期刊
VIRCHOWS ARCHIV
卷 461, 期 3, 页码 245-257出版社
SPRINGER
DOI: 10.1007/s00428-012-1281-4
关键词
Anaplastic lymphoma kinase; Rearrangement; Crizotinib; Algorithm; Guidelines; Non-small cell lung cancer
类别
资金
- Pfizer
In non-small cell lung cancer, epidermal growth factor receptor gene mutations and anaplastic lymphoma kinase (ALK) gene rearrangements have a major impact upon the level of response to treatment with specific tyrosine kinase inhibitors. This review describes the molecular basis of ALK inhibition, summarizes current data on the effectiveness and safety of ALK inhibition therapy, describes the different testing methodologies with their advantages and disadvantages, provides a suggested testing algorithm and puts forward a proposal for an external quality assessment program in ALK testing.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据